About this item:

57 Views | 6 Downloads

Author Notes:

Rebecca D. Levit, MD, 101 Woodruff Circle, Woodruff Memorial Building, Rm 319, Atlanta, GA 30322, Tel:404-712-9550, Fax: 404-727-3585, rlevit@emory.edu.

PFC and RDL are inventors on patent application submitted by Emory University that covers delivery device technology.

RDL is founder of CorAmi LLC which seeks to commercialize technology discussed in this paper, but provided no funds for this study.

AJG is technical consultant to CorAmi.

All other authors declare that they have no competing interests.

Subjects:

Research Funding:

This work was funded by the Coulter Translational Foundation and the Georgia Research Alliance.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • amiodarone
  • arrhythmias, cardiac
  • atrial fibrillation
  • hydrogel, polyethylene glycol
  • pericardium
  • AMERICAN-HEART-ASSOCIATION
  • LONG-TERM TREATMENT
  • QUALITY-OF-LIFE
  • RHYTHM CONTROL
  • INTRAPERICARDIAL DELIVERY
  • FAILURE
  • EFFICACY
  • DESETHYLAMIODARONE
  • INFARCTION
  • METABOLITE

Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial Fibrillation

Show all authors Show less authors

Tools:

Journal Title:

Circulation: Arrhythmia and Electrophysiology

Volume:

Volume 11, Number 5

Publisher:

, Pages e006408-e006408

Type of Work:

Article | Post-print: After Peer Review

Abstract:

BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although treatment options for AF exist, many patients cannot be maintained in normal sinus rhythm. Amiodarone is an effective medication for AF but has limited clinical utility because of off-target tissue toxicity. METHODS: Here, we use a pig model of AF to test the efficacy of an amiodarone-containing polyethylene glycol-based hydrogel. The gel is placed directly on the atrial epicardium through the pericardial space in a minimally invasive procedure using a specially designed catheter. RESULTS: Implantation of amiodarone-containing gel significantly reduced the duration of sustained AF at 21 and 28 days; inducibility of AF was reduced 14 and 21 days post-delivery. Off-target organ drug levels in the liver, lungs, thyroid, and fat were significantly reduced in animals treated with epicardial amiodarone gel compared with systemic controls in small-animal distribution studies. CONCLUSIONS: The pericardium is an underutilized therapeutic site and may be a new treatment strategy for AF and other cardiovascular diseases.

Copyright information:

© 2018 American Heart Association, Inc.

Export to EndNote